ESC HF 25: Secondary Analysis of FINEARTS-HF: Effects of Finerenone on Readmissions for HF

ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.

Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the efficacy and safety of finerenone on morbidity and mortality in patients with heart failure and left ventricular ejection fraction. The secondary analysis focuses on how finerenone effects the readmission rate for heart failure.

Findings showed finerenone treatment during or shortly after heart failure hospitalisation may be a safe and well tolerated option to reduce heart failure readmission rates; however, most outcomes were not statistically significant and the outcome requires further validation from the REDEFINE-HF trial.

Interview Questions:
1. What is the reasoning behind the secondary analysis of FINEARTS-HF?
2. What was the study design and patient population?
3. What were the key findings and how can they be used to identify patients who would benefit most from finerenone?
4. How should these findings impact clinical practice?
5. What further research is needed in this area?

Recorded on-site from ESC HF in Belgrade, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: Tom Green, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:   / radcliffecardiology  
Follow us on X: https://x.com/radcliffeCARDIO